Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Efficacy of an acellular pertussis vaccine among adolescents and adults.

Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, Edelman R, Edwards K; APERT Study Group.

N Engl J Med. 2005 Oct 13;353(15):1555-63.

2.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
3.

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R; APERT Study Group.

Clin Infect Dis. 2006 Jul 15;43(2):151-7. Epub 2006 Jun 5.

PMID:
16779740
4.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
5.

A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, Klein DL, Wassilak SG.

N Engl J Med. 1996 Feb 8;334(6):341-8.

6.

A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.

Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, uberall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P.

Pediatrics. 1998 Jan;101(1 Pt 1):1-11.

PMID:
9417143
7.

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J.

N Engl J Med. 1996 Feb 8;334(6):349-55. Erratum in: N Engl J Med 1996 May 2;334(18):1207.

8.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
10.

Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.

Heininger U, Cherry JD, Stehr K, Schmitt-Grohé S, Uberall M, Laussucq S, Eckhardt T, Meyer M, Gornbein J.

Pediatrics. 1998 Sep;102(3 Pt 1):546-53.

PMID:
9738175
12.

A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants.

Heininger U, Kleemann WJ, Cherry JD; Sudden Infant Death Syndrome Study Group.

Pediatrics. 2004 Jul;114(1):e9-15.

PMID:
15231967
13.

Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.

Langley JM, Halperin SA, Boucher FD, Smith B; Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC).

Pediatrics. 2004 Jul;114(1):e96-101.

PMID:
15231980
14.

Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.

Taranger J, Trollfors B, Bergfors E, Knutsson N, Lagergård T, Schneerson R, Robbins JB.

Pediatrics. 2001 Dec;108(6):E115. Review.

PMID:
11731642
15.

A placebo-controlled trial of a pertussis-toxoid vaccine.

Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB.

N Engl J Med. 1995 Oct 19;333(16):1045-50.

16.

Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life.

Tozzi AE, Ravà L, Ciofi degli Atti ML, Salmaso S; Progetto Pertosse Working Group.

Pediatrics. 2003 Nov;112(5):1069-75.

PMID:
14595048
17.

Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany.

Schläpfer G, Cherry JD, Heininger U, Uberall M, Schmitt-Grohé S, Laussucq S, Just M, Stehr K.

Pediatr Infect Dis J. 1995 Mar;14(3):209-14.

PMID:
7761186
18.

A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.

Christie CD, Garrison KM, Kiely L, Gupta RK, Heubi J, Marchant CD.

Clin Infect Dis. 2001 Oct 1;33(7):997-1003. Epub 2001 Sep 5.

PMID:
11528571
19.

Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG.

J Pediatr. 1998 Jun;132(6):983-8.

PMID:
9627590
20.

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.

Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, Meekison W, Eastwood BJ.

Pediatr Infect Dis J. 1999 Sep;18(9):772-9.

PMID:
10493336

Supplemental Content

Support Center